Acción 300841 CHENGDU KANGHUA BIOLOGICAL PRODUCTS CO., LTD.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Chengdu Kanghua Biological Products Co., Ltd.

Acciones

300841

CNE100003Y57

Precio de cierre Shenzhen S.E.
Otros sitios de cotización
 00:00:00 16/07/2024 		Varia. Cinco días. Varia. 1 de enero.
50,59 CNY -0,59 % Gráfico intradía de Chengdu Kanghua Biological Products Co., Ltd. +0,14 % -34,76 %
08/07 HilleVax interrumpirá el desarrollo de la vacuna contra el norovirus para lactantes; las acciones se desploman RE
29/04 Chengdu Kanghua Biological Products Co., Ltd. Ltd. anuncia el plan final de distribución de beneficios que se aplicará sobre las acciones A para el año 2023, pagadero el 08 de mayo de 2024 CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
HilleVax to discontinue development of norovirus vaccine for infants; shares plummet
Tranche Update on Chengdu Kanghua Biological Products Co., Ltd.'s Equity Buyback Plan announced on January 23, 2024.
Certain A Shares of Chengdu Kanghua Biological Products Co., Ltd. are subject to a Lock-Up Agreement Ending on 16-JUN-2024.
Chengdu Kanghua Biological Products Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2023, Payable on 08 May 2024
Chengdu Kanghua Biological Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Chengdu Kanghua Biological Products Co., Ltd. Proposes Final Cash Dividend for the Year 2023
Tranche Update on Chengdu Kanghua Biological Products Co., Ltd.'s Equity Buyback Plan announced on January 23, 2024.
Chengdu Kanghua Biological Products Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Chengdu Kanghua Biological Products Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.
Chengdu Kanghua Biological Products Co., Ltd. authorizes a Buyback Plan.
Kanghua Biological Products Licenses Norovirus Vaccine to HilleVax
Hillevax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China
Chengdu Kanghua Biological Products Co., Ltd.(SZSE:300841) dropped from Shenzhen Stock Exchange Component A Share Index
Chengdu Kanghua Biological Products Co., Ltd.(SZSE:300841) dropped from Shenzhen Stock Exchange Component Index
Jinan Kangyue Qiming Investment Partnership (Limited Partnership) completed the acquisition of 7.4% stake in Chengdu Kanghua Biological Products Co., Ltd. from Aokang Group Co., Ltd. and Wang Zhentao.
Chengdu Kanghua Biological Products Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Jinan Kangyue Qiming Investment Partnership (Limited Partnership) agreed to acquire 7.4% stake in Chengdu Kanghua Biological Products Co., Ltd. from Aokang Group Co., Ltd. and Wang Zhentao for approximately CNY550 million.
Chengdu Kanghua Biological Products Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Certain A Shares of Chengdu Kanghua Biological Products Co., Ltd. are subject to a Lock-Up Agreement Ending on 16-JUN-2023.
Chengdu Kanghua Biological Products Co., Ltd. Approves Cash Dividend for 2022, Payable on 24 May 2023
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción 300841
  4. Noticias Chengdu Kanghua Biological Products Co., Ltd.
  5. Otros idiomas